Operator: Greetings and welcome to Inhibikase Therapeutics First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial HypertensionBOSTON and ATLANTA, April 03, 2024 Inhibikase Therapeutics, Inc. , a.
Inhibikase Therapeutics (IKT) Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Inhibikase Therapeutics, Inc. (IKT) announced it will meet with the Office of Cardiology, Hematology, Endocrinology and Nephrology in the Division of Cardiology and Nephrology at the FDA for a Pre-IND meeting to discuss IkT-001Pro as a treatment for Pulmonary Arterial Hypertension.